Jennifer M. Loftis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jennifer M. Loftis has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
Peter Hauser
VA Long Beach Health Care System , Long Beach, California
26 shared publicationsMarilyn Huckans
Research & Development Service, Veterans Affairs Portland Health Care System, Portland, OR, USA
18 shared publications- Marilyn Huckans
Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd, Portland, OR 97239, USA
12 shared publications - Clare Wilhelm
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
8 shared publications Benjamin J. Morasco
Department of Psychiatry, Oregon Health & Science University; Research & Development Service, 3710 SW US Veterans Hospital Road, Portland Veterans Affairs Medical Center, Portland, Oregon, USA
7 shared publicationsRebekah Hudson
Research and Development Service, Veterans Affairs Portland Health Care System, Portland, OR, United States
7 shared publications
Latest Publications
- 23 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Establishing a Rodent Model of Venous Stent Thrombosis and In-Stent Restenosis
- 23 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Establishing a Rodent Model of Venous Stent Thrombosis and In-Stent Restenosis
- 22 January 2026
- Published by SAGE Publications in Journal of Attention Disorders
- Vol. 30 (6) , 727-746
Multinutrient Supplementation in Children With ADHD Reduced Pro- and Anti-Inflammatory Immune Factors in the MADDY Randomized Controlled Trial
Objective: While individual nutrients have shown effects on inflammatory mechanisms, the effects of multinutrients (vitamins + minerals, antioxidants, and amino acids) on inflammation are unknown. We investigated whether 8 weeks of multinutrient supplementation, in a randomized controlled trial of 83 children with ADHD, would alter immune factors compared to placebo. Methods: Multiplex technology was used to measure 25 immune factors in blood samples collected at baseline and week 8. Immune factors were compared between multinutrient and placebo groups using the Mann-Whitney test. Linear mixed effects models evaluated immune factor change over time. To understand the functional relevance of the immune factors affected by multinutrient supplementation, pathway analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.7 Bioinformatics Resources. Results: Interleukin (IL)-5 and IL-13 levels differed following multinutrient supplementation versus placebo ( p = .005 and .03, respectively). IL-5 decreased by 1.3% in the multinutrient group (95% CI [−8.6%, 6.7%]) and increased by 17.5% in the placebo group (95% CI [6.9%, 29.2%]). IL-13 decreased by 11.4% in the multinutrient group (95% CI [−18.2%, −4.0%]), compared to a 2.4% increase in the placebo group (95% CI [−7.2%, 13.1%]). When comparing immune factors between treatment responders versus non-responders in the multinutrient group, there was a 4.3% increase in IL-15 in multinutrient responders (95% CI [−6.8%, 16.8%]) and a 14.3% decrease in non-responders ( p = .03, 95% CI [−24.9%, −2.4%]). Pathway analysis identified T helper type 2 (Th2) signaling pathways affected by multinutrient supplementation, including IL-17 and cytokine-cytokine receptor interaction pathways. Conclusion: Th2 immune factors may be influenced by multinutrient supplementation and associated with behavioral improvements in ADHD.
- 22 January 2026
- Published by SAGE Publications in Journal of Attention Disorders
- Vol. 30 (6) , 727-746
Multinutrient Supplementation in Children With ADHD Reduced Pro- and Anti-Inflammatory Immune Factors in the MADDY Randomized Controlled Trial
Objective: While individual nutrients have shown effects on inflammatory mechanisms, the effects of multinutrients (vitamins + minerals, antioxidants, and amino acids) on inflammation are unknown. We investigated whether 8 weeks of multinutrient supplementation, in a randomized controlled trial of 83 children with ADHD, would alter immune factors compared to placebo. Methods: Multiplex technology was used to measure 25 immune factors in blood samples collected at baseline and week 8. Immune factors were compared between multinutrient and placebo groups using the Mann-Whitney test. Linear mixed effects models evaluated immune factor change over time. To understand the functional relevance of the immune factors affected by multinutrient supplementation, pathway analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.7 Bioinformatics Resources. Results: Interleukin (IL)-5 and IL-13 levels differed following multinutrient supplementation versus placebo ( p = .005 and .03, respectively). IL-5 decreased by 1.3% in the multinutrient group (95% CI [−8.6%, 6.7%]) and increased by 17.5% in the placebo group (95% CI [6.9%, 29.2%]). IL-13 decreased by 11.4% in the multinutrient group (95% CI [−18.2%, −4.0%]), compared to a 2.4% increase in the placebo group (95% CI [−7.2%, 13.1%]). When comparing immune factors between treatment responders versus non-responders in the multinutrient group, there was a 4.3% increase in IL-15 in multinutrient responders (95% CI [−6.8%, 16.8%]) and a 14.3% decrease in non-responders ( p = .03, 95% CI [−24.9%, −2.4%]). Pathway analysis identified T helper type 2 (Th2) signaling pathways affected by multinutrient supplementation, including IL-17 and cytokine-cytokine receptor interaction pathways. Conclusion: Th2 immune factors may be influenced by multinutrient supplementation and associated with behavioral improvements in ADHD.
- 25 February 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 402, 578567
Greater fatigue, disturbed sleep, persistent memory problems, and reduced CD4+ T cell and B cell percentages in adults with a history of methamphetamine dependence
- 25 February 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 402, 578567
Greater fatigue, disturbed sleep, persistent memory problems, and reduced CD4+ T cell and B cell percentages in adults with a history of methamphetamine dependence
- Open Access
- 15 December 2023
- Published by Taylor & Francis in Platelets
- Vol. 35 (1) , 2290916
Role of platelet count in a murine stasis model of deep vein thrombosis
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.
- 15 December 2023
- Published by Taylor & Francis in Platelets
- Vol. 35 (1) , 2290916
Open AccessRole of platelet count in a murine stasis model of deep vein thrombosis
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.
- 7 December 2023
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 116, 216-217
Seeking understanding and action for the neurologic consequences of SARS-CoV-2 infection
- 7 December 2023
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 116, 216-217
Seeking understanding and action for the neurologic consequences of SARS-CoV-2 infection
- Open Access
- 9 November 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1259041
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine
Introduction: Currently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, and adverse neuropsychiatric effects. We have shown that partial (p)MHC class II constructs (i.e., Recombinant T-cell receptor Ligand – RTL1000), comprised of the extracellular α1 and β1 domains of MHC class II molecules linked covalently to myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, can address the neuroimmune effects of methamphetamine addiction through its ability to bind to and down-regulate CD74 expression, block macrophage migration inhibitory factor (MIF) signaling, and reduce levels of pro-inflammatory chemokine ligand 2 (CCL2). The present study evaluated the effects of our third-generation pMHC II construct, DRmQ, on cognitive function and concentration of inflammatory cytokines in the frontal cortex, a region critical for cognitive functions such as memory, impulse control, and problem solving.Methods: Female and male C57BL/6J mice were exposed to methamphetamine (or saline) via subcutaneous (s.c.) injections administered four times per day every other day for 14 days. Following methamphetamine exposure, mice received immunotherapy (DRmQ or ibudilast) or vehicle s.c. injections daily for five days. Cognitive function was assessed using the novel object recognition test (NORT). To evaluate the effects of immunotherapy on inflammation in the frontal cortex, multiplex immunoassays were conducted. ANOVA was used to compare exploration times on the NORT and immune factor concentrations.Results: Post hoc analysis revealed increased novel object exploration time in MA-DRmQ treated mice, as compared to MA-VEH treated mice (non-significant trend). One-way ANOVA detected a significant difference across the groups in the concentration of macrophage inflammatory protein-2 (MIP-2) (p = 0.03). Post hoc tests indicated that mice treated with methamphetamine and DRmQ or ibudilast had significantly lower levels of MIP-2 in frontal cortex, as compared to mice treated with methamphetamine and vehicle (p > 0.05).Discussion: By specifically targeting CD74, our DRQ constructs can block the signaling of MIF, inhibiting the downstream signaling and pro-inflammatory effects that contribute to and perpetuate methamphetamine addiction.
- 9 November 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1259041
Open AccessImmunotherapeutic treatment of inflammation in mice exposed to methamphetamine
Introduction: Currently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, and adverse neuropsychiatric effects. We have shown that partial (p)MHC class II constructs (i.e., Recombinant T-cell receptor Ligand – RTL1000), comprised of the extracellular α1 and β1 domains of MHC class II molecules linked covalently to myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide, can address the neuroimmune effects of methamphetamine addiction through its ability to bind to and down-regulate CD74 expression, block macrophage migration inhibitory factor (MIF) signaling, and reduce levels of pro-inflammatory chemokine ligand 2 (CCL2). The present study evaluated the effects of our third-generation pMHC II construct, DRmQ, on cognitive function and concentration of inflammatory cytokines in the frontal cortex, a region critical for cognitive functions such as memory, impulse control, and problem solving.Methods: Female and male C57BL/6J mice were exposed to methamphetamine (or saline) via subcutaneous (s.c.) injections administered four times per day every other day for 14 days. Following methamphetamine exposure, mice received immunotherapy (DRmQ or ibudilast) or vehicle s.c. injections daily for five days. Cognitive function was assessed using the novel object recognition test (NORT). To evaluate the effects of immunotherapy on inflammation in the frontal cortex, multiplex immunoassays were conducted. ANOVA was used to compare exploration times on the NORT and immune factor concentrations.Results: Post hoc analysis revealed increased novel object exploration time in MA-DRmQ treated mice, as compared to MA-VEH treated mice (non-significant trend). One-way ANOVA detected a significant difference across the groups in the concentration of macrophage inflammatory protein-2 (MIP-2) (p = 0.03). Post hoc tests indicated that mice treated with methamphetamine and DRmQ or ibudilast had significantly lower levels of MIP-2 in frontal cortex, as compared to mice treated with methamphetamine and vehicle (p > 0.05).Discussion: By specifically targeting CD74, our DRQ constructs can block the signaling of MIF, inhibiting the downstream signaling and pro-inflammatory effects that contribute to and perpetuate methamphetamine addiction.
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S76
Comprehensive Outcomes After Cancer Health (COACH): Supporting Older Adults After Cancer Therapy
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S76
Comprehensive Outcomes After Cancer Health (COACH): Supporting Older Adults After Cancer Therapy
- Open Access
- 17 May 2023
- Published by Elsevier in Comprehensive Psychoneuroendocrinology
- Vol. 15, 100186
Inflammatory and mental health sequelae of COVID-19
- 17 May 2023
- Published by Elsevier in Comprehensive Psychoneuroendocrinology
- Vol. 15, 100186
Open AccessInflammatory and mental health sequelae of COVID-19
- 10 May 2022
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 217, 173403
A spotlight on HCV and SARS-CoV-2 co-infection and brain function
- 10 May 2022
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 217, 173403
A spotlight on HCV and SARS-CoV-2 co-infection and brain function